Dr Amol Akhade· @SuyogCancer · X·· 14 小时前评分70
正文 · 原文
DeLLphi-305. Immpresive curves . Additional Toxicity and cost in real world needs to be seen . Good for patients with extensive SCLC @myESMO @OncoAlert #esmo26
348 浏览 · 8 赞 · 5 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Dr Amol Akhade · x.com